TWI357329B - Pharmaceutical composition in the form of a gastri - Google Patents

Pharmaceutical composition in the form of a gastri Download PDF

Info

Publication number: TWI357329B
Authority: TW; Taiwan
Prior art keywords: pharmaceutical composition; crospovidone; tablet; mixture; povidone
Prior art date: 2004-08-19

Application number

TW094128210A

Other languages

English (en)

Chinese (zh)

Other versions

TW200618802A (en

Inventor

Gerard Alaux

Estelle Chouin

Nathalie Dufresne

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-19

Filing date

2005-08-18

Publication date

2012-02-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34950702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI357329(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-18 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2006-06-16 Publication of TW200618802A publication Critical patent/TW200618802A/zh

2012-02-01 Application granted granted Critical

2012-02-01 Publication of TWI357329B publication Critical patent/TWI357329B/zh

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 29
239000000203 mixture Substances 0.000 claims description 112
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 65
239000000546 pharmaceutical excipient Substances 0.000 claims description 45
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 33
229920002125 Sokalan® Polymers 0.000 claims description 32
229960000913 crospovidone Drugs 0.000 claims description 32
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 32
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 32
230000008961 swelling Effects 0.000 claims description 32
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 31
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 31
229940069328 povidone Drugs 0.000 claims description 31
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
238000002360 preparation method Methods 0.000 claims description 26
229920002689 polyvinyl acetate Polymers 0.000 claims description 24
239000011118 polyvinyl acetate Substances 0.000 claims description 24
239000004480 active ingredient Substances 0.000 claims description 23
229910000420 cerium oxide Inorganic materials 0.000 claims description 21
BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 claims description 21
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 20
YTNKWDJILNVLGX-UHFFFAOYSA-N alfuzosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 YTNKWDJILNVLGX-UHFFFAOYSA-N 0.000 claims description 20
229960003103 alfuzosin hydrochloride Drugs 0.000 claims description 20
239000008108 microcrystalline cellulose Substances 0.000 claims description 20
229940016286 microcrystalline cellulose Drugs 0.000 claims description 20
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 20
239000013563 matrix tablet Substances 0.000 claims description 19
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 14
235000019359 magnesium stearate Nutrition 0.000 claims description 14
-1 carboxyvinyl Chemical group 0.000 claims description 9
238000009472 formulation Methods 0.000 claims description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
230000002496 gastric effect Effects 0.000 claims description 6
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
229920002472 Starch Polymers 0.000 claims description 5
239000012530 fluid Substances 0.000 claims description 5
239000008107 starch Substances 0.000 claims description 5
235000019698 starch Nutrition 0.000 claims description 5
229960004607 alfuzosin Drugs 0.000 claims description 4
WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims description 4
239000011780 sodium chloride Substances 0.000 claims description 4
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
229960001631 carbomer Drugs 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
229910052742 iron Inorganic materials 0.000 claims description 3
230000003647 oxidation Effects 0.000 claims description 3
238000007254 oxidation reaction Methods 0.000 claims description 3
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 2
229960005168 croscarmellose Drugs 0.000 claims description 2
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
206010036790 Productive cough Diseases 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 claims 1
210000003802 sputum Anatomy 0.000 claims 1
208000024794 sputum Diseases 0.000 claims 1
235000021419 vinegar Nutrition 0.000 claims 1
239000000052 vinegar Substances 0.000 claims 1
239000003826 tablet Substances 0.000 description 106
239000010410 layer Substances 0.000 description 30
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 21
229920003085 Kollidon® CL Polymers 0.000 description 19
229920003084 Avicel® PH-102 Polymers 0.000 description 18
229910002016 Aerosil® 200 Inorganic materials 0.000 description 17
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
238000000034 method Methods 0.000 description 13
238000007906 compression Methods 0.000 description 12
230000006835 compression Effects 0.000 description 12
238000007907 direct compression Methods 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
VZMQWZVOXMCQKY-UHFFFAOYSA-L dimagnesium;octadecanoate Chemical compound [Mg+2].[Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O VZMQWZVOXMCQKY-UHFFFAOYSA-L 0.000 description 10
210000004051 gastric juice Anatomy 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
239000005557 antagonist Substances 0.000 description 4
INIZTEMZWOJCAF-UHFFFAOYSA-J dimagnesium octadecanoate Chemical compound [Mg+2].[Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O INIZTEMZWOJCAF-UHFFFAOYSA-J 0.000 description 4
239000002356 single layer Substances 0.000 description 4
NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 3
229960003036 amisulpride Drugs 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
229940032147 starch Drugs 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
WOPCCJAPUINYMV-UHFFFAOYSA-N 1-fluoro-n-phenylmethanesulfonamide Chemical compound FCS(=O)(=O)NC1=CC=CC=C1 WOPCCJAPUINYMV-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000011149 active material Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 2
229960005132 cisapride Drugs 0.000 description 2
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
229960003883 furosemide Drugs 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
229960005344 tiapride Drugs 0.000 description 2
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
TURGQPDWYFJEDY-UHFFFAOYSA-N 1-hydroperoxypropane Chemical compound CCCOO TURGQPDWYFJEDY-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
BVPWJMCABCPUQY-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003072 Plasdone™ povidone Polymers 0.000 description 1
229920003110 Primojel Polymers 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
MKRNVBXERAPZOP-UHFFFAOYSA-N Starch acetate Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OC(C)=O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 MKRNVBXERAPZOP-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229940056213 abilify Drugs 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
201000001883 cholelithiasis Diseases 0.000 description 1
229960001791 clebopride Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
229960000443 hydrochloric acid Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000007654 immersion Methods 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000004513 sizing Methods 0.000 description 1
239000012748 slip agent Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
229960001661 ursodiol Drugs 0.000 description 1
229960001968 veralipride Drugs 0.000 description 1
RYJXBGGBZJGVQF-UHFFFAOYSA-N veralipride Chemical compound COC1=CC(S(N)(=O)=O)=CC(C(=O)NCC2N(CCC2)CC=C)=C1OC RYJXBGGBZJGVQF-UHFFFAOYSA-N 0.000 description 1
239000010455 vermiculite Substances 0.000 description 1
229910052902 vermiculite Inorganic materials 0.000 description 1
235000019354 vermiculite Nutrition 0.000 description 1
229920001567 vinyl ester resin Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)

TW094128210A 2004-08-19 2005-08-18 Pharmaceutical composition in the form of a gastri TWI357329B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0408986A FR2874325B1 (fr)	2004-08-19	2004-08-19	Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine

Publications (2)

Publication Number	Publication Date
TW200618802A TW200618802A (en)	2006-06-16
TWI357329B true TWI357329B (en)	2012-02-01

Family

ID=34950702

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW094128210A TWI357329B (en)	2004-08-19	2005-08-18	Pharmaceutical composition in the form of a gastri

Country Status (22)

Country	Link
US (1)	US20070190140A1 (fr)
EP (1)	EP1781295A1 (fr)
JP (1)	JP5048492B2 (fr)
KR (1)	KR20070046124A (fr)
CN (1)	CN101022808B (fr)
AR (1)	AR050696A1 (fr)
AU (1)	AU2005276307B2 (fr)
BR (1)	BRPI0514532A (fr)
CA (1)	CA2577361C (fr)
EA (1)	EA012981B1 (fr)
FR (1)	FR2874325B1 (fr)
IL (1)	IL181150A0 (fr)
MA (1)	MA28862B1 (fr)
MX (1)	MX2007001957A (fr)
MY (1)	MY145832A (fr)
NO (1)	NO20071315L (fr)
NZ (1)	NZ553673A (fr)
PE (1)	PE20060639A1 (fr)
TW (1)	TWI357329B (fr)
UY (1)	UY29073A1 (fr)
WO (1)	WO2006021692A1 (fr)
ZA (1)	ZA200701443B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008080092A2 (fr)	2006-12-22	2008-07-03	Ironwood Pharmaceuticals, Inc.	Méthodes et compositions pour le traitement de troubles oesophagiens
WO2008102235A1 (fr) *	2007-02-20	2008-08-28	Aurobindo Pharma Limited	Formulations d'alfuzosine à libération contrôlée
JP2008280251A (ja) *	2007-05-08	2008-11-20	Shin Etsu Chem Co Ltd	多層錠及びその製造方法
EP2306823A4 (fr)	2008-06-30	2012-09-26	Tocagen Inc	Formulations de 5-fluorocytosine et leurs utilisations
JP5714562B2 (ja) *	2010-02-22	2015-05-07	第一三共株式会社	経口用徐放性固形製剤
WO2012027331A1 (fr)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
RU2545812C1 (ru) *	2014-02-24	2015-04-10	Аллан Герович Бениашвили	Ородисперсная таблетка дегидроэпиандростерона
US10245034B2 (en) *	2015-08-31	2019-04-02	Ethicon Llc	Inducing tissue adhesions using surgical adjuncts and medicants
US10569071B2 (en)	2015-08-31	2020-02-25	Ethicon Llc	Medicant eluting adjuncts and methods of using medicant eluting adjuncts
CN112426519A (zh) *	2020-11-29	2021-03-02	长沙晶易医药科技有限公司	一种含乙醇脱氢酶和乙醛脱氢酶的胃滞留缓释制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH630257A5 (en) *	1975-03-17	1982-06-15	Hoffmann La Roche	Sustained release formulation
DE4036757A1 (de) *	1990-11-17	1992-05-21	Bayer Ag	Antazida-zubereitung mit verlaengerter magenverweilzeit
IT1282650B1 (it) *	1996-02-19	1998-03-31	Jagotec Ag	Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
KR100364328B1 (ko) *	1996-08-29	2002-12-26	사노피-신델라보	알푸조신 염산염의 제어방출 정제
US6271278B1 (en) *	1997-05-13	2001-08-07	Purdue Research Foundation	Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US6197340B1 (en) *	1998-05-28	2001-03-06	Medical Research Institute	Controlled release lipoic acid
FR2784583B1 (fr) *	1998-10-16	2002-01-25	Synthelabo	Composition pharmaceutique a residence gastrique et a liberation controlee
US6632451B2 (en) *	1999-06-04	2003-10-14	Dexcel Pharma Technologies Ltd.	Delayed total release two pulse gastrointestinal drug delivery system
DE10014588A1 (de) *	2000-03-27	2001-10-04	Basf Ag	Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6476006B2 (en) *	2000-06-23	2002-11-05	Teva Pharmaceutical Industries, Ltd.	Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US7674480B2 (en) *	2000-06-23	2010-03-09	Teva Pharmaceutical Industries Ltd.	Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
JP2004501190A (ja) *	2000-06-23	2004-01-15	テバ　ファーマシューティカル　インダストリーズ　リミティド	治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
US6881424B1 (en) *	2000-09-05	2005-04-19	Mionix Corporation	Highly acidic metalated organic acid
FR2820319B3 (fr) *	2001-02-08	2003-12-05	Ellipse Pharmaceuticals	Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
BR0211317A (pt) *	2001-07-04	2004-12-14	Sun Pharmaceutical Ind Ltd	Sistema para a liberação controlada de uma droga por meio de retenção gástrica
US20040219186A1 (en) *	2001-08-16	2004-11-04	Ayres James W.	Expandable gastric retention device
US20030152622A1 (en) *	2001-10-25	2003-08-14	Jenny Louie-Helm	Formulation of an erodible, gastric retentive oral diuretic
US20030215526A1 (en) *	2002-03-08	2003-11-20	Scott Stofik	Stable formulations of angiotensin converting enzyme (ACE) inhibitors

2004
- 2004-08-19 FR FR0408986A patent/FR2874325B1/fr not_active Expired - Fee Related
2005
- 2005-08-04 PE PE2005000906A patent/PE20060639A1/es not_active Application Discontinuation
- 2005-08-16 AR ARP050103428A patent/AR050696A1/es not_active Application Discontinuation
- 2005-08-17 NZ NZ553673A patent/NZ553673A/en not_active IP Right Cessation
- 2005-08-17 JP JP2007526512A patent/JP5048492B2/ja not_active Expired - Fee Related
- 2005-08-17 KR KR1020077003897A patent/KR20070046124A/ko not_active Ceased
- 2005-08-17 AU AU2005276307A patent/AU2005276307B2/en not_active Ceased
- 2005-08-17 EP EP05798249A patent/EP1781295A1/fr not_active Withdrawn
- 2005-08-17 CA CA2577361A patent/CA2577361C/fr not_active Expired - Fee Related
- 2005-08-17 BR BRPI0514532-5A patent/BRPI0514532A/pt not_active IP Right Cessation
- 2005-08-17 MX MX2007001957A patent/MX2007001957A/es active IP Right Grant
- 2005-08-17 UY UY29073A patent/UY29073A1/es not_active Application Discontinuation
- 2005-08-17 CN CN2005800311527A patent/CN101022808B/zh not_active Expired - Fee Related
- 2005-08-17 EA EA200700217A patent/EA012981B1/ru not_active IP Right Cessation
- 2005-08-17 MY MYPI20053859A patent/MY145832A/en unknown
- 2005-08-17 WO PCT/FR2005/002092 patent/WO2006021692A1/fr not_active Ceased
- 2005-08-18 TW TW094128210A patent/TWI357329B/zh not_active IP Right Cessation
2007
- 2007-02-04 IL IL181150A patent/IL181150A0/en unknown
- 2007-02-16 US US11/675,712 patent/US20070190140A1/en not_active Abandoned
- 2007-02-19 ZA ZA2007/01443A patent/ZA200701443B/en unknown
- 2007-03-09 NO NO20071315A patent/NO20071315L/no not_active Application Discontinuation
- 2007-03-14 MA MA29756A patent/MA28862B1/fr unknown

Also Published As

Publication number	Publication date
JP5048492B2 (ja)	2012-10-17
PE20060639A1 (es)	2006-07-20
AU2005276307A1 (en)	2006-03-02
WO2006021692A8 (fr)	2007-04-12
HK1112575A1 (en)	2008-09-12
MX2007001957A (es)	2007-04-25
MY145832A (en)	2012-04-30
KR20070046124A (ko)	2007-05-02
JP2008509973A (ja)	2008-04-03
BRPI0514532A (pt)	2008-06-17
CN101022808A (zh)	2007-08-22
CA2577361C (fr)	2013-10-01
ZA200701443B (en)	2008-05-25
IL181150A0 (en)	2007-07-04
MA28862B1 (fr)	2007-09-03
NZ553673A (en)	2010-10-29
FR2874325A1 (fr)	2006-02-24
FR2874325B1 (fr)	2006-10-20
UY29073A1 (es)	2006-03-31
AR050696A1 (es)	2006-11-15
CA2577361A1 (fr)	2006-03-02
TW200618802A (en)	2006-06-16
EA200700217A1 (ru)	2007-08-31
EA012981B1 (ru)	2010-02-26
EP1781295A1 (fr)	2007-05-09
AU2005276307B2 (en)	2011-02-24
CN101022808B (zh)	2013-05-29
NO20071315L (no)	2007-03-09
WO2006021692A1 (fr)	2006-03-02
US20070190140A1 (en)	2007-08-16

Legal Events

Date	Code	Title	Description
2015-11-01	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
CA2182004C (fr)	2000-10-31	Comprimes enrobes de paracetamol et de domperidone
US20060127478A1 (en)	2006-06-15	Oral dosage formulation
KR101317592B1 (ko)	2013-10-15	프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
JP2005526043A5 (fr)	2006-01-05
AU2003275854B9 (en)	2009-08-27	Controlled-release compositions
US20070190140A1 (en)	2007-08-16	Pharmaceutical Composition in the Form of a Gastric-Resident Tablet Containing an Active Principle
JP2023513249A (ja)	2023-03-30	オメカムチブメカルビル製剤
HUP0203334A2 (hu)	2003-02-28	Közvetlen kompresszióval előállított polimer tabletta magok
TWI279232B (en)	2007-04-21	Delayed-release preparations of quinolone antibiotics and processes for their preparation
RU2540471C2 (ru)	2015-02-10	Препарат ацеклофенака с медленным высвобождением, оказывающий быстрое болеутоляющее и противовоспалительное действие, обеспечивающий оптимальное фармакологическое и клиническое действие при приеме один раз в день
KR101464771B1 (ko)	2014-11-26	페닐에프린의 지속 방출용 약제학적 조성물
WO2004019901A2 (fr)	2004-03-11	Composition pharmaceutique a liberation prolongee
WO2016062182A1 (fr)	2016-04-28	Préparation à libération prolongée de prégabaline
JP4177227B2 (ja)	2008-11-05	薬物の経口投与用徐放性組成物
MX2011001124A (es)	2011-03-29	Usos novedosos de formulaciones que contienen paracetamol.
TW200916127A (en)	2009-04-16	Extended release formulation of nevirapine
WO2011045775A1 (fr)	2011-04-21	Composition pharmaceutique à libération retardée de mésalamine
WO2004037228A1 (fr)	2004-05-06	Compositions a liberation prolongee contenant de l'alfuzosine
CA2853117C (fr)	2018-08-07	Composition pharmaceutique sublinguale contenant un antihistaminique et procede de preparation associe
AU2005256653B2 (en)	2010-10-14	Oral sustained release formulation of tedisamil with gastric retention properties
JP5826456B2 (ja)	2015-12-02	コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物
MX2007001973A (es)	2007-04-23	Extractor de jugo con contrapeso operativamente acoplado con un eje de levas.
KR20230158919A (ko)	2023-11-21	레바미피드를 포함하는 경구투여용 서방성 약학 조성물
AU2018301924B2 (en)	2021-07-29	Pharmaceutical compositions
HK1112575B (en)	2014-03-14	Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle